SCHEMBL468525

SCHEMBL468525

OC[C@@H](O)[C@H]1OC(c2ccccc2)O[C@@H](CO)[C@H]1O

nearest known ligand 0.44

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 9/20 0.43
SLC5A1 P13866 1/20 0.35
EPHX1 P07099 1/20 0.35
MANBA O00462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415299 1.00 SLC5A2 (0.43) SLC5A2SLC5A1EPHX1MANBA
SCHEMBL27526484 0.86 SLC5A2 (0.38) SLC5A2SLC5A1
SCHEMBL28928268 0.86 EPHX1 (0.35) SLC5A2SLC5A1EPHX1
SCHEMBL28774531 0.86 SLC5A2 (0.40) SLC5A2SLC5A1
SCHEMBL28649385 0.85 SLC5A2 (0.39) SLC5A2SLC5A1
SCHEMBL20373569 0.85 EPHX1 (0.34) SLC5A2SLC5A1EPHX1MANBA
SCHEMBL7681079 0.83 SLC5A2 (0.49) SLC5A2SLC5A1
SCHEMBL9809746 0.83 SLC5A2 (0.37) SLC5A2
SCHEMBL28650376 0.82 SLC5A2 (0.49) SLC5A2SLC5A1
SCHEMBL27554109 0.82 SLC5A2 (0.38) SLC5A2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8231884-B2 Polymer or surfactant enveloping oriented fibers; mass formed by 3:2,4-di-O-benzylidene-D-sorbitol organogelator; oblong particles have beneficial iridescent properties; soft-focus effect properties; make-up and foundation improve visual appearance of skin PIERRE FABRE DERMO-COSMETIQUE (FR) 2012-07-31 US claimed
US-20080248071-A1 Diffusing Particles Based on Organogelling Xerogel Fibers, Method for Preparing Same and Use in Cosmetic Formulations PIERRE FABRE DERMO-COSMETIQUE (FR) 2008-10-09 US claimed
US-11697735-B2 Solid oleaginous compositions TOTAL MARKETING SERVICES (FR) 2023-07-11 US disclosed
US-11365317-B2 Solid binders TOTAL MARKETING SERVICES (FR) 2022-06-21 US disclosed
EP-3612616-B1 SOLID BITUMEN AT AMBIENT TEMPERATURE TOTAL MARKETING SERVICES (FR) 2022-06-01 EP disclosed
US-11332606-B2 Clear binder that is solid when cold TOTAL MARKETING SERVICES (FR) 2022-05-17 US disclosed
CN-110050035-B Solid oleaginous compositions 道达尔销售服务公司 2022-05-13 CN disclosed
US-20220145079-A1 BITUMINOUS COMPOSITION SOLID AT AMBIENT TEMPERATURE TOTAL MARKETING SERVICES (FR) 2022-05-12 US disclosed
EP-3510103-B1 CLEAR SOLID COLD BINDER TOTAL MARKETING SERVICES (FR) 2022-02-16 EP disclosed
US-11242287-B2 Bitumen which is solid at ambient temperature TOTAL MARKETING SERVICES (FR) 2022-02-08 US disclosed
US-11198105-B2 Method for manufacturing material in the form of granules that can be used as road binder or sealing binder and device for manufacturing same TOTAL MARKETING SERVICES (FR) 2021-12-14 US disclosed
EP-1778709-B1 POLYSULFATED GLYCOSIDES AND SALTS THEREOF IVAX DRUG RES INST LTD (HU) 2008-05-28 EP disclosed
US-20070281893-A1 Polysulfated Glycosides And Salts Thereof IVAX DRUG RESEARCH INSTITUTE LTD (HU) 2007-12-06 US disclosed
WO-2007098597-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2007-09-07 WO disclosed
WO-2007098597-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2007-09-07 WO disclosed
EP-1778709-A2 POLYSULFATED GLYCOSIDES AND SALTS THEREOF IVAX Drug Research Institute Ltd (HU) 2007-05-02 EP disclosed
WO-2007039561-A1 DIFFUSING PARTICLES BASED ON ORGANOGELLING XEROGEL FIBERS, METHOD FOR PREPARING SAME AND USE IN COSMETIC FORMULATIONS PIERRE FABRE DERMO-COSMETIQUE (FR) 2007-04-12 WO disclosed
CN-1303076-C Asymmetric benzaldehyde alditol derivatives, methods of making thereof, and compositions and articles containing same MILLIKEN & CO (US) 2007-03-07 CN disclosed
US-20060247222-A1 Glycosidase inhibitors and methods of synthesizing same SIMON FRASER UNIVERSITY (CA) 2006-11-02 US disclosed
WO-2006017726-A2 POLYSULFATED GLYCOSIDES AND SALTS THEREOF IVAX DRUG RESEARCH INSTITUTE LTD (HU) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080248071-A1 Diffusing Particles Based on Organogelling Xerogel Fibers, Method for Preparing Same and Use in Cosmetic Formulations SORD, DPM1, SUCLG1 SLC5A2 1924/4885SLC5A1 2916/4885EPHX1 4528/4885
US-20060247222-A1 Glycosidase inhibitors and methods of synthesizing same STS, SCLY, MGAM SLC5A2 12/4885SLC5A1 19/4885EPHX1 1200/4885
US-20070281893-A1 Polysulfated Glycosides And Salts Thereof CFTR, AREG, STS SLC5A2 292/4885SLC5A1 195/4885EPHX1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.